Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The actin
motor protein
non-muscle myosin II (NMII) acts as a master regulator of cell morphology, with a role in several essential cellular processes, including cell migration and post-synaptic dendritic spine plasticity in neurons. NMII also generates forces that alter biochemical signaling, by driving changes in interactions between actin-associated proteins that can ultimately regulate gene transcription. In addition to its roles in normal cellular physiology, NMII has recently emerged as a critical regulator of diverse, genetically complex diseases, including neuronal disorders, cancers and vascular disease. In the context of these disorders, NMII regulatory pathways can be directly mutated or indirectly altered by disease-causing mutations. NMII regulatory pathway genes are also increasingly found in disease-associated copy-number variants, particularly in neuronal disorders such as
autism
and schizophrenia. Furthermore, manipulation of NMII-mediated contractility regulates stem cell pluripotency and differentiation, thus highlighting the key role of NMII-based pharmaceuticals in the clinical success of stem cell therapies. In this Review, we discuss the emerging role of NMII activity and its regulation by kinases and microRNAs in the pathogenesis and prognosis of a diverse range of diseases, including neuronal disorders, cancer and vascular disease. We also address promising clinical applications and limitations of NMII-based inhibitors in the treatment of these diseases and the development of stem-cell-based therapies.
...
PMID:Non-muscle myosin II in disease: mechanisms and therapeutic opportunities. 2654 4
Synaptic transmission is a fundamental molecular process underlying learning and memory. Successful synaptic transmission involves coupled interaction between electrical signals (action potentials) and chemical signals (neurotransmitters). Defective synaptic transmission has been reported in a variety of neurological disorders such as
Autism
and Alzheimer's disease. A large variety of macromolecules and organelles are enriched near functional synapses. Although a portion of macromolecules can be produced locally at the synapse, a large number of synaptic components especially the membrane-bound receptors and peptide neurotransmitters require active transport machinery to reach their sites of action. This spatial relocation is mediated by energy-consuming,
motor protein
-driven cargo trafficking. Properly regulated cargo trafficking is of fundamental importance to neuronal functions, including synaptic transmission. In this review, we discuss the molecular machinery of cargo trafficking with emphasis on new experimental strategies that enable direct modulation of cargo trafficking in live cells. These strategies promise to provide insights into a quantitative understanding of cargo trafficking, which could lead to new intervention strategies for the treatment of neurological diseases.
...
PMID:Drive the Car(go)s-New Modalities to Control Cargo Trafficking in Live Cells. 2816 71
Myosin XVI (Myo16), a vertebrate-specific
motor protein
, is a recently discovered member of the myosin superfamily. The detailed functionality regarding myosin XVI requires elucidating or clarification; however, it appears to portray an important role in neural development and in the proper functioning of the nervous system. It is expressed in the largest amount in neural tissues in the late embryonic-early postnatal period, specifically the time in which neuronal cell migration and dendritic elaboration coincide. The impaired expression of myosin XVI has been found lurking in the background of several neuropsychiatric disorders including
autism
, schizophrenia and/or bipolar disorders.Two principal isoforms of class XVI myosins have been thus far described: Myo16a, the tailless cytoplasmic isoform and Myo16b, the full-length molecule featuring both cytoplasmic and nuclear localization. Both isoforms contain a class-specific N-terminal ankyrin repeat domain that binds to the protein phosphatase catalytic subunit. Myo16b, the predominant isoform, exhibits a diverse function. In the cytoplasm, it participates in the reorganization of the actin cytoskeleton through activation of the PI3K pathway and the WAVE-complex, while in the nucleus it may possess a role in cell cycle regulation. Based on the sequence, myosin XVI may have a compromised ATPase activity, implying a potential stationary role.
...
PMID:Myosin XVI. 3245 69
Myosin Va (MyoVa) is a plus-end filamentous-actin
motor protein
that is highly and broadly expressed in the vertebrate body, including in the nervous system. In excitatory neurons MyoVa transports cargo toward the tip of the dendritic spine, where the post-synaptic density (PSD) is formed and maintained. MyoVa mutations in humans cause neurological dysfunction, intellectual disability, hypomelanation and death in infancy or childhood. Here we characterize the Flailer (Flr) mutant mouse, which is homozygous for a
myo5a
mutation that drives high levels of mutant MyoVa (Flr protein) specifically in the CNS. Flr protein functions as a dominant-negative MyoVa, sequestering cargo and blocking its transport to the PSD. Flr mice have early seizures and mild ataxia, but mature and breed normally. Flr mice display several abnormal behaviors known to be associated with brain regions that show high expression of Flr protein. Flr mice are defective in the transport of synaptic components to the PSD and in mGluR-dependent LTD and have a reduced number of mature dendritic spines. The synaptic and behavioral abnormalities of Flr mice result in an anxiety and memory deficits similar to that of other mouse mutants with Obsessive-compulsive disorder and Autism spectrum disorder (ASD). Because of the dominant-negative nature of the Flr protein, the Flr mouse offers a powerful system for the analysis of how the disruption of synaptic transport and lack of LTD can alter synaptic function, development and wiring of the brain and result in symptoms that characterize many neuropsychiatric disorders.
SIGNIFICANCE STATEMENT
Here we characterize a mutant mouse homozygous for a Myosin Va mutation named Flailer. The Flailer mutation generates a dominant-negative MyoVa transport
motor protein
that sequesters synaptic cargo and blocks synaptic transport, thereby resulting in an absence of LTD and in abnormal behaviors similar to those seen in anxiety and
Autism
Spectrum disorders. We propose that the Flailer mutant can be used as a model to study how the absence of LTD disrupts brain connectivity and behavior. Moreover, by using the Flailer mutation together with gene editing technologies it should be possible to target specific brain areas to remove the mutation and recover MyoVa function, thereby interrogating the role of a specific brain region in the control of a particular behavior.
...
PMID:Myosin Va Brain-Specific Mutation Alters Mouse Behavior and Disrupts Hippocampal Synapses. 3322 12